

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

**MEDICAL TECHNOLOGIES EVALUATION
PROGRAMME**

Equality impact assessment – Guidance development

**The UroLift System for the treatment of lower urinary
tract symptoms of benign prostatic hyperplasia**

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

Consultation

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how? |
|---|

No equality issues were identified during the scoping process.
--

- | |
|--|
| 2. Have any other potential equality issues been highlighted in the sponsor's submission, or patient organisation questionnaires, and, if so, how has the Committee addressed these? |
|--|

No potential equality issues have been identified.
--

The incidence of BPE/BPH increases with age. No equality issues were identified by the Committee during selection and routing, but it was noted that age is a protected characteristic defined in the Equality Act, 2010.

- | |
|---|
| 3. Have any other potential equality issues been identified by the Committee and, if so, how has the Committee addressed these? |
|---|

It was noted that lower urinary tract symptoms of BPH are more prevalent in black men than men of white or Asian origin. This is a function of the clinical condition, not of the technology.

No changes to the preliminary recommendations were needed as a result of these considerations.
--

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to or difficulties with access for the specific group?

The preliminary recommendations do not hinder access to the technology for any specific group.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No potential adverse impact has been identified.

6. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

Not applicable.

7. Have the Committee's considerations of equality issues been described in the medical technology consultation document, and, if so, where?

No potential equality issues have been identified.

Approved by Associate Director (name): Mark Campbell

Date: 14 September 2015

Medical technologies guidance document

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?

No equality issues were identified during the consultation.

The incidence of BPE/BPH increases with age. No equality issues were identified by the Committee during consultation, but it was noted that age is a protected characteristic defined in the Equality Act, 2010.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to access for the specific group?

The recommendations were not changed following consultation, other than editing for clarification. The final recommendations do not restrict access to the device by any specific group.

3. If the recommendations have changed after consultation, is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No potential adverse impact has been identified.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

No barriers, difficulties or other equality issues have been identified.

5. Have the Committee's considerations of equality issues been described in the medical technologies guidance document, and, if so, where?

No equality issues have been identified.

Approved by Programme Director (name): Mirella Marlow

Date: 15 September 2015